Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zaurategrast in Relapsing MS
NCT00484536Phase 2
Key facts
- Status
- Terminated
- Start
- May 2007
- Primary completion
- Nov 2009
- Countries
- 11
- Sponsor
- UCB
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Drugs
- zaurategrast
- Conditions
- multiple sclerosis (MS)
01
Overview
Phase 2, randomised, double-blind trial of zaurategrast in multiple sclerosis (MS) (3 arms), sponsored by UCB. Primary endpoint: Cumulative number of newly active lesions on standardized brain MRI scans at 28 weeks. Started May 2007; status: terminated.
02
Design
3 arms- Study design
- RandomizedDouble-blind
CDP323 1000 mg/day
CDP323 500 mg bid
CDP323 500 mg/day
CDP323 500 mg once daily
Placebo
Placebo capsules once daily
03
Who it enrols
Patients with relapsing forms of MS, EDSS 0-5.5, active disease on MRI, and failed prior treatment with beta-interferons or glatiramer acetate.
04
Endpoints
Primary
Cumulative number of newly active lesions on standardized brain MRI scans
Secondary
Occurrence of any treatment emergent adverse event
Beyond the preview
Go deeper on NCT00484536.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484536.